Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 5Completed 3Terminated 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 96Lung Neoplasms 38Neoplasms 10Mesothelioma, Malignant 9Mesothelioma 8Adenocarcinoma of Lung 8Small Cell Lung Carcinoma 7Neoplasm Metastasis 7Thoracic Neoplasms 5Recurrence 5Lung Diseases 5Carcinoma 5Respiratory Tract Neoplasms 4Carcinoma, Bronchogenic 4Brain Neoplasms 4Respiratory Tract Diseases 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Neoplasms by Histologic Type 3NSCLC 3Head and Neck Neoplasms 3Bronchial Neoplasms 3Adenocarcinoma, Bronchiolo-Alveolar 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Neoplasms, Nerve Tissue 2Melanoma 2

Interventions

pembrolizumab 51Ipilimumab 49Cyclophosphamide 43Nivolumab 40aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10spartalizumab 9cobimetinib 9binimetinib 9Radiotherapy 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Melanoma × Pemetrexed × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡